Trump Administration Advances Medicare Drug Price Negotiation Amid Industry Concerns
The Trump administration proceeds with the third cycle of Medicare drug price negotiations, addressing Part B drug inclusion and sparking pharmaceutical industry concerns about pricing and implementation.